“These prices are a joke. If a legitimate partne
Post# of 148110
I think people forgot but this is a platform drug. We are talking 100 billion dollar company someday or 20 billion when MRK offers us this in 2027 after shareholders are completely burnt out.”
Spot on, we must keep perspective. With billions of dollars in revenue we won’t need your grandmother!
Per Dr Google who doth foretell Leronlimab’s future as a platform drug:
“Merck's Keytruda rolled to $25 billion in sales in 2023, which likely made it the world's top-selling drug in 2023. (Merck & Co.) With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world's top-selling drug in 2023.”